



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,  
Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 29<sup>th</sup> May, 2024

To,

The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code: 532815**

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Subject: Statement of deviation or variation in utilisation of funds raised through Preferential Issue for the quarter ended 31<sup>st</sup> March, 2024**

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD1/162/2019 dated December 24, 2019, please find enclosed herewith the statement of deviation or variation in utilisation of funds raised through preferential issue for the quarter ended 31<sup>st</sup> March, 2024.

We request to kindly take note of the same

Thanking you


Yours faithfully

**For SMS Pharmaceuticals Limited**

**Thirumalesh Tumma  
Company Secretary**

**Statement of Deviation / Variation in utilisation of funds raised through Preferential Allotment**

<b>Name of listed entity</b>	SMS Pharmaceuticals Limited					
<b>Mode of Fund Raising</b>	Preferential Issue					
<b>Date of Raising Funds</b>	19 <sup>th</sup> March, 2024 (Allotment of 90,00,000 convertible warrants upon receipt of 25% of the issue price at Rs.127/- per warrant)					
<b>Amount Raised</b>	Rs. 28,57,50,000/-					
<b>Report filed for Quarter ended</b>	31 <sup>st</sup> March, 2024					
<b>Monitoring Agency</b>	Applicable					
<b>Monitoring Agency Name, if applicable</b>	M/s. CARE Ratings Limited					
<b>Is there a Deviation / Variation in use of funds raised</b>	No					
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not Applicable					
<b>If Yes, Date of shareholder Approval</b>	Not Applicable					
<b>Explanation for the Deviation / Variation</b>	Not Applicable					
<b>Comments of the Audit Committee after review</b>	Nil					
<b>Comments of the auditors, if any</b>	Nil					
<b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>						
<b>Original Object</b>	<b>Modified Object, if any</b>	<b>Original Allocation</b>	<b>Modified allocation, if any</b>	<b>Funds Utilised till 31<sup>st</sup> March, 2024</b>	<b>Amount of Deviation/Variation for the quarter according to applicable object</b>	<b>Remarks if any</b>
The proceeds of the Preferential issue shall be utilized to meet the Capital Expenditure requirement for Expansion of production capacities in phased manner and installation of additional utility equipment's as well as	Not Applicable	Rs. 28,57,50,000/-	Not Applicable	Rs. 28,57,00,000/-	NIL	-



<p>recovery systems. Proposed to start backward integration of Key Starting Materials (KSM) for existing as well as new products under pipeline at R&amp;D by setting up new production blocks. Further, it may be utilized to meet Working Capital Requirement and General Purpose also.</p>						
---	--	--	--	--	--	--

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

For SMS Pharmaceuticals Limited



Lakshmi Narayana Tammineedi  
Chief Financial Officer

Place: Hyderabad

Date: 29.05.2024